WANY
NBIX icon

Wealthspire Advisors (New York)’s Neurocrine Biosciences NBIX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-456
Closed -$64K – 2209
2025
Q3 		$64K Buy
+456
New +$61.8K ﹤0.01% 1149
2019
Q1 		– Sell
-5
Closed – – 530
2018
Q4 		$0 Buy
+5
New +$479 ﹤0.01% 906

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wealthspire Advisors (New York)'s NBIX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 456 shares — an estimated $64K sold.

Wealthspire Advisors (New York) first reported a position in NBIX in Q4 2018 and held it in 2 quarters. The position peaked at $64K in Q3 2025. 731 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 456 Neurocrine Biosciences shares in Q4 2025, an estimated $64K.
  • Wealthspire Advisors (New York) first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 2 quarters.
  • Wealthspire Advisors (New York)'s Neurocrine Biosciences position peaked at $64K in Q3 2025.
  • 731 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.